NervGen Pharma Corp
NervGen Pharma Corp

Analyst Coverage

FirmAnalyst
Raymond JamesMichael Freeman
Stifel GMPJustin Keywood
Encode Ideas, LPHogan Mullally
Paradigm CapitalScott McAuley, PhD

NervGen Pharma Corp. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of NervGen Pharma Corp. or its management. NervGen Pharma Corp. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

NervGen Pharma Corp

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: info@nervgen.com

Twitter Facebook-f Youtube Linkedin
Subscribe for Updates
DOWNLOAD OUR PRESENTATION
Twitter Facebook-f Youtube Linkedin
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.